NCT00240318已完成3 期
A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 450
- 试验地点
- 61
- 主要终点
- to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS
研究概览
简要总结
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.
排除标准
- •Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week wash-out period following which a baseline lipid profile will be taken at visit
- •Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.
结局指标
主要结局
to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS
次要结局
- to evaluate whether treatment with rosuvastatin results in:
- Regression of coronary artery atheroma burden, as assessed by TAV
- Regression of coronary artery disease as measured by quantitative coronary angiography (QCA).
- To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
- To evaluate the safety of rosuvastatin
研究者
研究点 (61)
Loading locations...
相似试验
Unknown
4 期
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)HyperlipidemiaAtherosclerosisNCT00885872Chinese PLA General Hospital60
已完成
3 期
Rosuvastatin Impact on Ventricular Remodelling Lipids and CytokinesHeart Failure, CongestiveNCT00240292AstraZeneca160
Unknown
4 期
Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques VolumeCoronary Artery DiseaseHyperlipidemiaNCT01382277Peking University First Hospital600
已完成
4 期
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic SyndromeMetabolic SyndromeNCT00815659AstraZeneca97
已完成
3 期
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatinFamilial HypercholesterolemiaNCT00355615AstraZeneca173